InvestorsHub Logo
Followers 0
Posts 204
Boards Moderated 0
Alias Born 04/08/2004

Re: moberylane post# 7412

Thursday, 06/19/2008 9:02:31 AM

Thursday, June 19, 2008 9:02:31 AM

Post# of 12383
I have believed for some time that ENMD 1198 was selected for development in order to provide Panzem's potential without it's bioavailability problems. This thought allows dropping future oncology development for Panzem without having to see any bad news.

The source of the company's confidence remains a critical curiousity in the face of future funding issues. Maybe we'll have some good news real soon now.

Regards to all.